UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer

International journal of molecular sciences, 2023-04, Vol.24 (8), p.6945

2023

Volltextzugriff (PDF)

A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer

Current cancer drug targets, 2015-10, Vol.15 (8), p.665-683

2015

Volltextzugriff (PDF)

Gene Expression Profiling in Early Breast Cancer-Patient Stratification Based on Molecular and Tumor Microenvironment Features

Biomedicines, 2022-01, Vol.10 (2), p.248

2022

Volltextzugriff (PDF)

MicroRNAs: a complex regulatory network drives the acquisition of malignant cell phenotype

Endocrine-related cancer, 2010-03, Vol.17 (1), p.F51-F75

2010

Volltextzugriff (PDF)

Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers

Current pharmaceutical design, 2013-02, Vol.19 (5), p.864-882

2013

Volltextzugriff (PDF)

Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma

International Journal of Endocrinology, 2013-01, Vol.2013, p.803171-16

2013

Volltextzugriff (PDF)

Integrated MicroRNA-mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer

International journal of molecular sciences, 2017-01, Vol.18 (1), p.194-194

2017

Volltextzugriff (PDF)

Abstract PO2-03-07: Immune Landscape in PD-L1-positive and TROP2-positive Triple-Negative Breast Cancer

Cancer research (Chicago, Ill.), 2024-05, Vol.84 (9_Supplement), p.PO2-03-07-PO2-03-07

2024

Volltextzugriff (PDF)

Abstract PO2-03-08: Uncovering Novel Potential Prognostic Biomarkers in Basal-Like Breast Cancer using Transcriptomic Data of 1,899 Patients

Cancer research (Chicago, Ill.), 2024-05, Vol.84 (9_Supplement), p.PO2-03-08-PO2-03-08

2024

Volltextzugriff (PDF)

Role of inflammation in obesity-related breast cancer

Current opinion in pharmacology, 2016-12, Vol.31, p.114-122

2016

Volltextzugriff (PDF)

Targeting microRNAs as key modulators of tumor immune response

Journal of experimental & clinical cancer research, 2016-06, Vol.35 (1), p.103-103, Article 103

2016

Volltextzugriff (PDF)

Breast cancer assessment tools and optimizing adjuvant therapy

Nature reviews. Clinical oncology, 2010-12, Vol.7 (12), p.725-732

2010

Volltextzugriff (PDF)

Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis

Journal of thoracic oncology, 2022-01, Vol.17 (1), p.103-115

2022

Volltextzugriff (PDF)

Progress in nonviral gene therapy for breast cancer and what comes next?

Expert opinion on biological therapy, 2017-05, Vol.17 (5), p.595-611

2017

Volltextzugriff (PDF)

Abstract P5-02-04: Immune Signatures Display Subtype-Specific Activation in Breast Cancer

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.P5-P5-02-04

2023

Volltextzugriff (PDF)

Circulating tumour cells and cell-free DNA as tools for managing breast cancer

Nature reviews. Clinical oncology, 2013-07, Vol.10 (7), p.377-389

2013

Volltextzugriff (PDF)

Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS1108-TPS1108

2022

Volltextzugriff (PDF)

An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers

Breast cancer research : BCR, 2016-12, Vol.18 (1), p.121-121, Article 121

2016

Volltextzugriff (PDF)

miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4), p.927-939

2016

Volltextzugriff (PDF)

HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS1115-TPS1115

2023

Volltextzugriff (PDF)

Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers

Current pharmaceutical design, 2012-12, Vol.19 (5), p.864-882

2012

Volltextzugriff (PDF)

Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes

International journal of cancer, 2016-01, Vol.138 (1), p.87-97

2016

Volltextzugriff (PDF)

Long-term Eradication of Locally Recurrent Invasive Follicular Thyroid Carcinoma after Taxane-based Concomitant Chemoradiotherapy

Anticancer research, 2009-11, Vol.29 (11), p.4665-4671

2009

Volltextzugriff (PDF)

Immune gene signatures in triple-negative breast cancers characterized by varying levels of chromosomal instability

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.1096-1096

2017

Volltextzugriff (PDF)

Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients

Cancer, 2012-05, Vol.118 (10), p.2603-2614

2012

Volltextzugriff (PDF)

1 – 25 von 87

Suche als RSS-Feed

Aktive Filter

SpracheJapanisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(84)
Mit Volltextzugriff
(70)

Publikationsform

Sprache

Englisch
(87)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer

A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer

Gene Expression Profiling in Early Breast Cancer-Patient Stratification Based on Molecular and Tumor Microenvironment Features

MicroRNAs: a complex regulatory network drives the acquisition of malignant cell phenotype

Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers

Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma

Integrated MicroRNA-mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer

Abstract PO2-03-07: Immune Landscape in PD-L1-positive and TROP2-positive Triple-Negative Breast Cancer

Abstract PO2-03-08: Uncovering Novel Potential Prognostic Biomarkers in Basal-Like Breast Cancer using Transcriptomic Data of 1,899 Patients

Role of inflammation in obesity-related breast cancer

Targeting microRNAs as key modulators of tumor immune response

Breast cancer assessment tools and optimizing adjuvant therapy

Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis

Progress in nonviral gene therapy for breast cancer and what comes next?

Abstract P5-02-04: Immune Signatures Display Subtype-Specific Activation in Breast Cancer

Circulating tumour cells and cell-free DNA as tools for managing breast cancer

Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)

An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers

miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer

HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer

Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers

Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes

Long-term Eradication of Locally Recurrent Invasive Follicular Thyroid Carcinoma after Taxane-based Concomitant Chemoradiotherapy

Immune gene signatures in triple-negative breast cancers characterized by varying levels of chromosomal instability

Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients

Aktive Filter

Suchergebnisse filtern